Protective Effect of Erythropoietin and Its Carbamylated Derivative in Experimental Cisplatin Peripheral Neurotoxicity
暂无分享,去创建一个
P. Ghezzi | A. Cerami | G. Nicolini | G. Cavaletti | G. Lauria | A. Ronchi | C. Minoia | V. Rodriguez-Menendez | M. Brines | A. Canta | R. Lombardi | P. Penza | R. Bianchi | C. Savino | N. Oggioni | A. Gilardini | Paola Penza
[1] M. Stillman,et al. Chemotherapy-induced peripheral neuropathy. , 2005, Oncology nursing forum.
[2] G. Nicolini,et al. Intraepidermal nerve fiber density in rat foot pad: neuropathologic–neurophysiologic correlation , 2005, Journal of the peripheral nervous system : JPNS.
[3] E. Ferrannini,et al. Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vessels. , 2005, European heart journal.
[4] A. Hoke,et al. A novel endogenous erythropoietin mediated pathway prevents axonal degeneration , 2004, Annals of neurology.
[5] S. Sallah,et al. Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model. , 2004, Cancer letters.
[6] P. Ghezzi,et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[7] C. Bokemeyer,et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. , 2004, European journal of cancer.
[8] Z. Erbayraktar,et al. Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic , 2004, Science.
[9] Justin C McArthur,et al. The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. , 2004, Brain : a journal of neurology.
[10] P. Ghezzi,et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[11] F. Zunino,et al. Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] J. Glass,et al. Calpain inhibition protects against Taxol-induced sensory neuropathy. , 2003, Brain : a journal of neurology.
[13] R. Myers,et al. Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury , 2003, The European journal of neuroscience.
[14] Z. Erbayraktar,et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[15] M. Buemi,et al. The Pleiotropic Effects of Erythropoietin in the Central Nervous System , 2003, Journal of neuropathology and experimental neurology.
[16] M. Gassmann,et al. Erythropoietin‐induced excessive erythrocytosis activates the tissue endothelin system in mice , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[17] P. Lewczuk,et al. Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial , 2002, Molecular medicine.
[18] S. Lipton,et al. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades , 2001, Nature.
[19] R. Myers,et al. Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[20] P. Lewczuk,et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[21] M. Gassmann,et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[22] P Ghezzi,et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[23] H. Eichler,et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. , 2000, Blood.
[24] T. Golper,et al. Impaired Biological Activity of Erythropoietin by Cyanate Carbamylation , 2000, Blood Purification.
[25] G. Cavaletti,et al. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. , 1999, Neurotoxicology.
[26] M. Miloso,et al. Effect of Recombinant Human Nerve Growth Factor on Cisplatin Neurotoxicity in Rats , 1999, Experimental Neurology.
[27] D. Gershenson,et al. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. McArthur,et al. Epidermal nerve fiber density: normative reference range and diagnostic efficiency. , 1998, Archives of neurology.
[29] J. McArthur,et al. Neuropathological alterations in diabetic truncal neuropathy: evaluation by skin biopsy , 1998, Journal of neurology, neurosurgery, and psychiatry.
[30] M. Markman,et al. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. , 1996, Gynecologic oncology.
[31] J. Holst,et al. Neuropeptides and Morphological Changes in Cisplatin-Induced Dorsal Root Ganglion Neuronopathy , 1996, Experimental Neurology.
[32] G. Cavaletti,et al. Protective effects of glutathione on cisplatin neurotoxicity in rats. , 1994, International journal of radiation oncology, biology, physics.
[33] G. Cavaletti,et al. Off-treatment course of cisplatin-induced dorsal root ganglia neuronopathy in rats. , 1994, In vivo.
[34] K. L. Davis,et al. Alanine scanning mutagenesis of human erythropoietin identifies four amino acids which are critical for biological activity. , 1993, European journal of biochemistry.
[35] J. Arezzo,et al. Nerve growth factor prevents experimental cisplatin neuropathy , 1992, Annals of neurology.
[36] V. Lim. Recombinant human erythropoietin in predialysis patients. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[37] J. Arezzo,et al. Nerve growth factor prevents toxic neuropathy in mice , 1991, Annals of neurology.
[38] N. Casadevall,et al. Erythropoietin: physiology and clinical experience. , 1990, Seminars in hematology.
[39] H. Kozutsumi,et al. Chemical modification of erythropoietin: an increase in in vitro activity by guanidination. , 1990, Biochimica et biophysica acta.
[40] A. Raine. HYPERTENSION, BLOOD VISCOSITY, AND CARDIOVASCULAR MORBIDITY IN RENAL FAILURE: IMPLICATIONS OF ERYTHROPOIETIN THERAPY , 1988, The Lancet.
[41] G. Cavaletti,et al. Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration , 2004, Journal of Neuro-Oncology.
[42] S. Muftuoglu,et al. Erythropoietin against cisplatin-induced peripheral neurotoxicity in rats , 2004, Medical oncology.
[43] S. Lipton,et al. Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[44] I. Barajon,et al. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats , 2004, Acta Neuropathologica.
[45] R. Labianca,et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] S. Cascinu,et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] G. Cavaletti,et al. Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. , 1994, Neurotoxicology.